Table 1. Patient characteristics.
| Characteristics | Total | Children, 0–12.9 yr | Adolescent, 13–18.9 yr | Young adult, 19–24.9 yr | P valuea | P valueb | ||
|---|---|---|---|---|---|---|---|---|
| No. of patients | 224 (100) | 74 (100) | 99 (100) | 51 (100) | ||||
| Sex | < 0.001 | 0.004 | ||||||
| Male | 146 (65.2) | 58 (78.4) | 66 (66.7) | 22 (43.1) | ||||
| Female | 78 (34.8) | 16 (21.6) | 33 (33.3) | 29 (56.9) | ||||
| Male-to-female ratio | 1.87 | 3.62 | 2.00 | 0.79 | ||||
| Histology | 0.012 | 0.001 | ||||||
| NP | 21 (9.4) | 7 (9.5) | 9 (9.1) | 5 (9.8) | ||||
| cHL-NS | 128 (57.1) | 29 (39.2) | 67 (67.7) | 32 (62.7) | ||||
| cHL-LR | 17 (7.6) | 8 (10.8) | 5 (5.1) | 4 (7.8) | ||||
| cHL-MC | 57 (25.4) | 30 (40.5) | 17 (17.2) | 10 (19.6) | ||||
| cHL-LD | 1 (0.4) | 0 (0) | 1 (1.0) | 0 (0) | ||||
| Ann Arbor stage | 0.424 | 0.119 | ||||||
| I | 27 (12.1) | 14 (18.9) | 9 (9.1) | 4 (7.8) | ||||
| II | 96 (42.9) | 27 (36.5) | 45 (45.5) | 24 (47.1) | ||||
| III | 44 (19.6) | 16 (21.6) | 18 (18.2) | 10 (19.6) | ||||
| IV | 57 (25.4) | 17 (23.0) | 27 (27.3) | 13 (25.5) | ||||
| Stage | 0.718 | 0.508 | ||||||
| Limited | 81 (36.2) | 29 (39.2) | 33 (33.3) | 19 (37.3) | ||||
| Advanced | 143 (63.8) | 45 (60.8) | 66 (66.7) | 32 (62.7) | ||||
| Risk | 0.043 | 0.010 | ||||||
| Low | 81 (36.2) | 32 (43.2) | 32 (32.3) | 17 (33.3) | ||||
| Intermediate | 101 (45.1) | 23 (31.1) | 50 (50.5) | 28 (54.9) | ||||
| High | 42 (18.8) | 19 (25.7) | 17 (17.2) | 6 (11.8) | ||||
| B-symptoms | 0.704 | 0.405 | ||||||
| Yes | 53 (23.7) | 20 (27.0) | 22 (22.2) | 11 (21.6) | ||||
| No | 171 (76.3) | 54 (73.0) | 77 (77.8) | 40 (78.4) | ||||
| Bone marrow | 0.703 | 0.432 | ||||||
| Yes | 13 (5.8) | 3 (4.1) | 7 (7.1) | 3 (5.9) | ||||
| No | 211 (94.2) | 71 (95.9) | 92 (92.9) | 48 (94.1) | ||||
| Spleen | 0.680 | 0.771 | ||||||
| Yes | 40 (17.9) | 14 (18.9) | 19 (19.2) | 7 (13.7) | ||||
| No | 184 (82.1) | 60 (81.1) | 80 (80.8) | 44 (86.3) | ||||
| Bulky | 0.023 | 0.066 | ||||||
| Yes | 63 (28.1) | 15 (20.3) | 37 (37.4) | 11 (21.6) | ||||
| Mediastinal mass | 49 (21.9) | 8 (10.8) | 30 (30.3) | 11 (21.6) | ||||
| Non-mediastinal mass | 15 (6.7) | 7 (9.5) | 8 (8.1) | 0 (0) | ||||
| No | 161 (71.9) | 59 (79.7) | 62 (62.6) | 40 (78.4) | ||||
| Extra-nodal | 0.201 | 0.183 | ||||||
| Yes | 70 (31.3) | 18 (24.3) | 32 (32.3) | 20 (39.2) | ||||
| No | 154 (68.8) | 56 (75.7) | 67 (67.7) | 31 (60.8) | ||||
| No. of extra-nodal sites | 0.310 | 0.129 | ||||||
| 1 | 44 (19.6) | 8 (10.8) | 22 (22.2) | 14 (27.5) | ||||
| 2 | 17 (7.6) | 7 (9.5) | 7 (7.1) | 3 (5.9) | ||||
| ≥ 3 | 9 (4.0) | 3 (4.1) | 3 (3.0) | 3 (5.9) | ||||
| Location | ||||||||
| Above diaphragm | - | 66 (89.2) | 91 (91.9) | 49 (96.1) | 0.379 | 0.283 | ||
| Below diaphragm | - | 23 (37.8) | 32 (32.3) | 15 (29.4) | 0.935 | 0.969 | ||
Data are presented as number (%).
cHL = classic Hodgkin's lymphoma, NP = nodular lymphocyte predominant, NS = nodular sclerosis, LR = lymphocyte rich, MC = mixed cellularity, LD = lymphocyte depletion.
aP values were calculated among children, adolescent and young adult; bP values were calculated between children and adolescent + young adult.